Breaking Finance News

Nivalis Therapeutics Inc (NASDAQ:NVLS) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Nivalis Therapeutics Inc (NASDAQ:NVLS) to Sell in a statement released on 10/12/2016.

On 9/13/2016, Raymond James released a statement for Nivalis Therapeutics Inc (NASDAQ:NVLS) bumped up the target price from $0.00 to $20.00 that suggested an upside of 1.57%.

Boasting a price of $7.38, Nivalis Therapeutics Inc (NASDAQ:NVLS) traded 0.00% even on the day. With the last stock price close up 40.75% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Nivalis Therapeutics Inc has recorded a 50-day average of $7.61 and a two hundred day average of $5.40. Volume of trade was up over the average, with 72,734 shares of NVLS changing hands over the typical 62,234

Recent Performance Chart

Nivalis Therapeutics Inc (NASDAQ:NVLS)

Nivalis Therapeutics Inc has with a one year low of $3.68 and a one year high of $9.45 and has a market capitalization of $0.

General Company Details For Nivalis Therapeutics Inc (NASDAQ:NVLS)

Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *